Research
Hormonal
Intensive blood pressure control (target <130/80 mmHg) reduces stroke and macroalbuminuria progression in type 2 diabetes compared to conventional control, without significantly affecting all-cause mortality.
If you have diabetes, aim for a blood pressure target below 130/80 mmHg, especially if you have kidney disease or heart risks. This significantly lowers your risk of stroke and kidney damage. Use home monitoring to get a true average, as clinic readings can be misleading.
StrongQualifiesHIGH confidence
A meta-analysis of nine trials of 11 005 people with type 2 diabetes randomized to intensive blood pressure (BP) control (mean 125/73) vs conventional treatment (mean 134/79) showed 36% reduction in stroke and 32% reduction in progression to macroalbuminuria, although CVD and all-cause mortality rates were similar at the two BP levels
Why this rating
Based on meta-analyses of multiple randomized controlled trials.
Source
A diabetes update
Zachary T. Bloomgarden · Journal of Diabetes · 2023
DOI 10.1111/1753-0407.13434
narrative_reviewCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (e.g., tirzepatide, danuglipron) produce significant weight loss and glycemic improvement in type 2 diabetes and obesity, with weight loss and glycemic effects being partially independent mechanisms.Good
- Once-weekly insulin icodec provides glycemic control similar to once-daily insulin glargine with comparable hypoglycemia rates, potentially improving patient acceptability through reduced injection frequency.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →